Combivir

Company
GlaxoSmithKline

Approval Status
Approved September 1997

Treatment for
AIDS, HIV Infection

Areas
Immune System

The U.S. Food and Drug Administration approved the first one-pill combination of the two most widely used antiretroviral medications for AIDS and HIV infection. Combivir, a combination of Retrovir (zidovudine or AZT) and Epivir (lamivudine or 3TC), could decrease the number of pills people with HIV have to take daily.

Side effects include: nausea, diarrhea, anemia, low white blood cells, pancreatitis and neuropathy.

Combivir Drug Information

The Combivir drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top